诸城这家公司拟上市！

Core Viewpoint - Shandong Xinde Technology Co., Ltd. has submitted its prospectus to the Hong Kong Stock Exchange for a main board listing, aiming to expand its production capacity and enhance R&D in new vaccines and pet medications [2][4] Company Overview - Founded in 1999 and registered in Weifang, Shandong, Xinde Technology is a leading animal health company in China, focusing on the R&D, production, and sales of veterinary biological products, traditional Chinese veterinary medicine, chemical drug formulations, feed, and feed additives [2] - The company ranks 9th among domestic manufacturers in China's animal health market with a market share of approximately 1.4%, and is among the top three in the poultry veterinary biological products market [2] Financial Performance - For the years 2023, 2024, and the first nine months of 2025, the company's revenue was reported at 985 million yuan, 982 million yuan, and 877 million yuan respectively, with gross profit margins of 49.7%, 50.8%, and 55.3% [2] - Net profits for the same periods were 34.76 million yuan, 28.12 million yuan, and 55.67 million yuan [2] - Overseas revenue has seen significant growth, increasing from 12.2 million yuan in 2023 to 46.1 million yuan in the first nine months of 2025, with products entering markets such as Pakistan, Egypt, and Vietnam [2] Strategic Initiatives - The company plans to use the funds raised from the IPO primarily to expand its production base and capacity, enhance R&D investment in new vaccines and pet medications, and expand its domestic and international sales networks [4] - The controlling shareholder is Chairman and President Li Chaoyang, who holds 45.08% of the voting rights, with Sumitomo Corporation, a Fortune Global 500 company, as a strategic shareholder [4]